Completed

Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from past medical records and data - Retrospective
Who is being recruted

Chronic Disease+5

+ Lung Diseases

+ Lung Diseases, Obstructive

Over 40 Years
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: December 2019
See protocol details

Summary

Principal SponsorBoehringer Ingelheim
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 29, 2019

Actual date on which the first participant was enrolled.

Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or LAMA treatment

Official TitleTaiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease
NCT04011475
Principal SponsorBoehringer Ingelheim
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1617 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 40 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic DiseaseLung DiseasesLung Diseases, ObstructivePathologic ProcessesRespiratory Tract DiseasesPathological Conditions, Signs and SymptomsDisease AttributesPulmonary Disease, Chronic Obstructive

Criteria

Inclusion Criteria: Patients who fulfil ALL the following criteria are included. 1. Patients who diagnosed with COPD who were prescribed with LABA/LABA (FDC or free combo) as a new initiation or switching from other therapy (i.e., single/dual/triple), or newly receiving LAMA treatment for 3 months at least prior to 30 June 2018 2. Male or female patients ≥ 40 years of age Exclusion Criteria: 1\. Patients who meet the following criterion are not included. * Patients with documented diagnosis of bronchial asthma, asthma-COPD overlap syndrome (ACOS), bronchiectasis, cystic fibrosis, or lung cancer

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 12 locations

Suspended

Ditmanson Medical Foundation Chia - Yi Christian Hospital

Chia YI City, TaiwanOpen Ditmanson Medical Foundation Chia - Yi Christian Hospital in Google Maps
Suspended

CGMH Chia YI

Chia YI City, Taiwan
Suspended

Eda hospital

Kaohsiung City, Taiwan
Suspended

CGMH Kaohsiung

Kaohsiung City, Taiwan
Completed12 Study Centers
Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease | PatLynk